Logo

Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy

Share this

Roche Reports Results of Risdiplam in FIREFISH Study for Infants with Type 1 Spinal Muscular Atrophy

Shots:

  • The FIREFISH study involves assessing of Risdiplam in infants aged 1-7 mos. with Type 1 SMA
  • The P-II FIREFISH study results: met its 1EPs i.e- the proportion of infants sitting without support for at least 5sec @12mos. of treatment- assessed by the Gross Motor Scale of BSID-III- consistent safety profile with no new safety signals
  • Risdiplam is an investigational SMN2 splicing modifier for SMA- currently being evaluated in 4 multicenter studies and has received US FDA’s PR status with its expected approval by 24 May- 2019

Click here ­to­ read full press release/ article 

 Ref: GlobeNewswire | Image: Roche 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions